SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscanTM technology platform.
The biggest constraint on successful development of a high-throughput proteomic quantitation platform is achieving sufficient sensitivity. SomaLogic's innovative SOMAmer (Slow Off-rate Modified Aptamer) protein-capture reagents and their multiplex SOMAscan technology break through this limitation.
AmberGen has developed a range of novel molecules and compounds with photocleavable linkers, including a 5-prime photocleavable biotin, a light-activated biomolecule that it has licensed to SomaLogic. "AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our SOMAscan- platform" said Nick Saccomano, Ph.D., Chief Technology Officer at SomaLogic.
The SOMAscan- technology platform utilizes SOMAmers to accurately screen dozens of patient samples simultaneously, allowing quantification of many specific proteins in a multiplexed, high-throughput manner. SomaLogic has thus far validated SOMAmers to a broad array of over 1000 different protein targets for use in biomarker discovery, diagnostics, and drug discovery and development.
"We look forward to exploring new applications for our photocleavable technologies with SomaLogic, as we continue to support their existing and emerging SOMAmer reagents," stated Christopher Sears, Ph.D., Chief Scientific Officer of AmberGen. "With both companies' commitment to developing tools for personalized medicine, there are ample opportunities for further collaboration."
Protein-packed foods may not be as healthy as you think, study finds